|
Today's Headlines
Actavis plc on Friday said it filed an Abbreviated New Drug Application (ANDA) with FDA seeking approval to market ambrisentan tablets, a generic version of Gilead Sciences, Inc.'s Letairis, a treatment for pulmonary arterial hypertension.
» Suit unfolds
|
|
Coverage of specialty pharmaceuticals varies widely among health insurers, according to a new report from Atlantic Information Services in Washington, D.C.
» Read more
|
Continuing Education
Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month's activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.
Read/print the article: Click here
Take the test: Click here to log in with the Session Code 15DT16-TAJ88.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
Consumer advocacy group Public Citizen said FDA must stop direct-to-consumer advertisements that market several "dangerous" diabetes medications for weight loss or blood pressure reduction. » Details
|
|
|
Like
Tweet
